Judith Klimovsky
Corporate Officer/Principal at GENMAB A/S
Net worth: 3 M $ as of 30/03/2024
Profile
Judith Klimovsky is a professional who currently holds the position of Chief Development Officer & Executive VP at Genmab A since 2017.
Prior to this, she worked as Senior Vice President & Head-Clinical Development at Novartis AG and Novartis Pharma AG from 2009 to 2017.
She also worked as a Director at Bellicum Pharmaceuticals, Inc. from 2018 to 2024.
Dr. Klimovsky holds a doctorate degree from the University of Buenos Aires School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GENMAB A/S
0.01% | 13/02/2024 | 8,740 ( 0.01% ) | 3 M $ | 30/03/2024 |
Judith Klimovsky active positions
| Companies | Position | Start |
|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 08/02/2017 |
Former positions of Judith Klimovsky
| Companies | Position | End |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 22/02/2024 |
| NOVARTIS AG | Corporate Officer/Principal | 31/01/2017 |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 31/12/2016 |
Training of Judith Klimovsky
| University of Buenos Aires School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| GENMAB A/S | Health Technology |
| Private companies | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Judith Klimovsky
